Back to Search
FELIPE SAMANIEGO, MD, MPH
MD, MPH
Medical Oncology Physician
NPI: 1871675249Individual
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
K9896(TX)
Research & Publications (20)
Vascular endothelial growth factor and Kaposi's sarcoma cells in human skin grafts.
PMID 12193477·Cell Growth Differ·2002
7-preclinical
Human herpesvirus 8 K1-associated nuclear factor-kappa B-dependent promoter activity: role in Kaposi's sarcoma inflammation?
PMID 11158202·J Natl Cancer Inst Monogr·2001
7-preclinical
Mechanism of Fas signaling regulation by human herpesvirus 8 K1 oncoprotein.
PMID 19276446·J Natl Cancer Inst·2009
7-preclinical
Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment.
PMID 19237479·Ann Oncol·2009
8-other
Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma.
PMID 19150940·Ann Oncol·2009
8-other
Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma.
PMID 18764869·Br J Haematol·2008
3-trial
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.
PMID 18411419·Blood·2008
3-trial
Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma.
PMID 18085611·Cancer·2008
3-trial
The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma.
PMID 18083690·Ann Oncol·2008
8-other
Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma.
PMID 17608763·Br J Haematol·2007
3-trial
Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways.
PMID 17317853·Blood·2007
7-preclinical
Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma.
PMID 17233846·Br J Haematol·2007
3-trial
K1 protein of human herpesvirus 8 suppresses lymphoma cell Fas-mediated apoptosis.
PMID 17090655·Blood·2007
8-other
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
PMID 16145068·J Clin Oncol·2005
3-trial
Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha.
PMID 15741224·Blood·2005
3-trial
Activation of Src kinase Lyn by the Kaposi sarcoma-associated herpesvirus K1 protein: implications for lymphomagenesis.
PMID 15665117·Blood·2005
7-preclinical
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
PMID 15613697·J Clin Oncol·2005
3-trial
Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.
PMID 15353540·J Clin Oncol·2004
3-trial
Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease.
PMID 15328181·Clin Cancer Res·2004
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1515 HOLCOMBE BLVD, 77030-4009
HOUSTON, TX 77030 - Phone
- (713) 792-6161
Quick Facts
- NPI
- 1871675249
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile